Publications by authors named "Marie Paquet"
Purpose: We evaluated the prognostic value of immunotherapy-induced organ inflammation observed on FDG PET in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs).
Methods: Data from patients with IIIB/IV NSCLC included in two different prospective trials were analyzed. FDG PET/CT exams were performed at baseline (PET) and repeated after 7-8 weeks (PET1) and 12-16 weeks (PET2) of treatment, using iPERCIST for tumor response evaluation.
Background: Reliable predictive and prognostic markers are still lacking for patients treated with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC). The purpose of this study was to investigate the prognostic and predictive values of different baseline metabolic parameters, including metabolic tumor volume (MTV), from 18F-fluorodeoxyglucose positron emission tomography-computed tomography (F-FDG PET/CT) scans in patients with NSCLC treated with PD1 inhibitors.
Methods: Maximum and peak standardized uptake values, MTV and total lesion glycolysis (TLG), as well as clinical and biological parameters, were recorded in 75 prospectively included patients with NSCLC treated with PD1 inhibitors.
Background: Human trials combining external radiotherapy (RT) and metallic nanoparticles are currently underway in cancer patients. For internal RT, in which a radioisotope such as radioiodine is systemically administered into patients, there is also a need for enhancing treatment efficacy, decreasing radiation-induced side effects and overcoming radio-resistance. However, if strategies vectorising radioiodine through nanocarriers have been documented, sensitizing the neoplasm through the use of nanotherapeutics easily translatable to the clinic in combination with the standard systemic radioiodine treatment has not been assessed yet.
View Article and Find Full Text PDFArticle Synopsis
- Jérôme Barriere was unintentionally left out of the initial article.
- He played a key role in designing the study and writing the protocol.
- Barriere was also involved in including a significant number of patients in the research.
Purpose: This study aimed to assess the therapeutic impact and diagnostic accuracy of F-DOPA PET/CT in patients with glioblastoma or brain metastases.
Methods: Patients with histologically proven glioblastoma or brain metastases were prospectively included in this monocentric clinical trial (IMOTEP). Patients were included either due to a clinical suspicion of relapse or to assess residual tumor infiltration after treatment.
Purpose: Oncogenic osteomalacia is an endocrine disorder induced by small benign tumours (TIO) producing excessive fibroblast growth factor-23 (FGF23). The only way of curing oncogenic osteomalacia is surgical resection of the culprit TIO, which is extremely difficult to detect using conventional imaging modalities due to its small size and variable location in the body. Since TIO frequently overexpress somatostatin receptors, a clinical utility of SPECT or PET with radiolabelled somatostatin analogues has been reported.
View Article and Find Full Text PDFArticle Synopsis
- * This study reveals that the viral gene m138 is responsible for causing the rapid loss of the costimulatory molecule B7-1 (CD80) from the surface of DC, impacting their ability to activate CD8+ T cells.
- * The research findings indicate that m138 interferes with the secretory pathway of B7-1 by redirecting it to specific compartments, marking the first time a viral protein has been shown to target B7-1 in MCMV infections.